-
XW0D Mouth and Pharynx
-
XW0D0 Open
-
XW0D00 Brexanolone
-
XW0D00 Spesolimab Monoclonal Antibody
-
XW0D01 Daratumumab and Hyaluronidase-fihj
-
XW0D01 Eladocagene exuparvovec
-
XW0D02 Bromelain-enriched Proteolytic Enzyme
-
XW0D02 Nerinitide
-
XW0D03 Durvalumab Antineoplastic
-
XW0D03 Maribavir Anti-infective
-
XW0D04 Teclistamab Antineoplastic
-
XW0D05 Mosunetuzumab Antineoplastic
-
XW0D05 Narsoplimab Monoclonal Antibody
-
XW0D06 Afamitresgene Autoleucel Immunotherapy
-
XW0D06 Lefamulin Anti-infective
-
XW0D06 Terlipressin
-
XW0D07 Coagulation Factor Xa, Inactivated
-
XW0D07 Tabelecleucel Immunotherapy
-
XW0D07 Trilaciclib
-
XW0D08 Lurbinectedin
-
XW0D08 Mineral-based Topical Hemostatic Agent
-
XW0D08 Treosulfan
-
XW0D08 Uridine Triacetate
-
XW0D09 Ceftolozane/Tazobactam Anti-infective
-
XW0D09 Inebilizumab-cdon
-
XW0D09 Satralizumab-mwge
-
XW0D0A Cefiderocol Anti-infective
-
XW0D0A Ciltacabtagene Autoleucel
-
XW0D0B Amivantamab Monoclonal Antibody
-
XW0D0B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW0D0B Omadacycline Anti-infective
-
XW0D0C Eculizumab
-
XW0D0C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW0D0D Atezolizumab Antineoplastic
-
XW0D0D Engineered Allogeneic Thymus Tissue
-
XW0D0E Etesevimab Monoclonal Antibody
-
XW0D0E Remdesivir Anti-infective
-
XW0D0F Bamlanivimab Monoclonal Antibody
-
XW0D0F Other New Technology Therapeutic Substance
-
XW0D0G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW0D0G Plazomicin Anti-infective
-
XW0D0G REGN-COV2 Monoclonal Antibody
-
XW0D0G Sarilumab
-
XW0D0H Axicabtagene Ciloleucel Immunotherapy
-
XW0D0H Other New Technology Monoclonal Antibody
-
XW0D0H Synthetic Human Angiotensin II
-
XW0D0H Tocilizumab
-
XW0D0J Apalutamide Antineoplastic
-
XW0D0J Tisagenlecleucel Immunotherapy
-
XW0D0K Fosfomycin Anti-infective
-
XW0D0K Idecabtagene Vicleucel Immunotherapy
-
XW0D0K Leronlimab Monoclonal Antibody
-
XW0D0L CD24Fc Immunomodulator
-
XW0D0L Erdafitinib Antineoplastic
-
XW0D0L Lifileucel Immunotherapy
-
XW0D0M Baricitinib
-
XW0D0M Brexucabtagene Autoleucel Immunotherapy
-
XW0D0M Esketamine Hydrochloride
-
XW0D0N Lisocabtagene Maraleucel Immunotherapy
-
XW0D0N Meropenem-vaborbactam Anti-infective
-
XW0D0P Antibiotic-eluting Bone Void Filler
-
XW0D0Q Tagraxofusp-erzs Antineoplastic
-
XW0D0R Fostamatinib
-
XW0D0R Venetoclax Antineoplastic
-
XW0D0S COVID-19 Vaccine Dose 1
-
XW0D0S Iobenguane I-131 Antineoplastic
-
XW0D0T COVID-19 Vaccine Dose 2
-
XW0D0T Ruxolitinib
-
XW0D0U COVID-19 Vaccine
-
XW0D0U Imipenem-cilastatin-relebactam Anti-infective
-
XW0D0V COVID-19 Vaccine Dose 3
-
XW0D0V Gilteritinib Antineoplastic
-
XW0D0W Caplacizumab
-
XW0D0W COVID-19 Vaccine Booster
-
XW0D0X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW0D0X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW0D0Y Other New Technology Monoclonal Antibody
-
-
XW0D3 Percutaneous
-
XW0D30 Brexanolone
-
XW0D30 Spesolimab Monoclonal Antibody
-
XW0D31 Daratumumab and Hyaluronidase-fihj
-
XW0D31 Eladocagene exuparvovec
-
XW0D32 Bromelain-enriched Proteolytic Enzyme
-
XW0D32 Nerinitide
-
XW0D33 Durvalumab Antineoplastic
-
XW0D33 Maribavir Anti-infective
-
XW0D34 Teclistamab Antineoplastic
-
XW0D35 Mosunetuzumab Antineoplastic
-
XW0D35 Narsoplimab Monoclonal Antibody
-
XW0D36 Afamitresgene Autoleucel Immunotherapy
-
XW0D36 Lefamulin Anti-infective
-
XW0D36 Terlipressin
-
XW0D37 Coagulation Factor Xa, Inactivated
-
XW0D37 Tabelecleucel Immunotherapy
-
XW0D37 Trilaciclib
-
XW0D38 Lurbinectedin
-
XW0D38 Mineral-based Topical Hemostatic Agent
-
XW0D38 Treosulfan
-
XW0D38 Uridine Triacetate
-
XW0D39 Ceftolozane/Tazobactam Anti-infective
-
XW0D39 Inebilizumab-cdon
-
XW0D39 Satralizumab-mwge
-
XW0D3A Cefiderocol Anti-infective
-
XW0D3A Ciltacabtagene Autoleucel
-
XW0D3B Amivantamab Monoclonal Antibody
-
XW0D3B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW0D3B Omadacycline Anti-infective
-
XW0D3C Eculizumab
-
XW0D3C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW0D3D Atezolizumab Antineoplastic
-
XW0D3D Engineered Allogeneic Thymus Tissue
-
XW0D3E Etesevimab Monoclonal Antibody
-
XW0D3E Remdesivir Anti-infective
-
XW0D3F Bamlanivimab Monoclonal Antibody
-
XW0D3F Other New Technology Therapeutic Substance
-
XW0D3G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW0D3G Plazomicin Anti-infective
-
XW0D3G REGN-COV2 Monoclonal Antibody
-
XW0D3G Sarilumab
-
XW0D3H Axicabtagene Ciloleucel Immunotherapy
-
XW0D3H Other New Technology Monoclonal Antibody
-
XW0D3H Synthetic Human Angiotensin II
-
XW0D3H Tocilizumab
-
XW0D3J Apalutamide Antineoplastic
-
XW0D3J Tisagenlecleucel Immunotherapy
-
XW0D3K Fosfomycin Anti-infective
-
XW0D3K Idecabtagene Vicleucel Immunotherapy
-
XW0D3K Leronlimab Monoclonal Antibody
-
XW0D3L CD24Fc Immunomodulator
-
XW0D3L Erdafitinib Antineoplastic
-
XW0D3L Lifileucel Immunotherapy
-
XW0D3M Baricitinib
-
XW0D3M Brexucabtagene Autoleucel Immunotherapy
-
XW0D3M Esketamine Hydrochloride
-
XW0D3N Lisocabtagene Maraleucel Immunotherapy
-
XW0D3N Meropenem-vaborbactam Anti-infective
-
XW0D3P Antibiotic-eluting Bone Void Filler
-
XW0D3Q Tagraxofusp-erzs Antineoplastic
-
XW0D3R Fostamatinib
-
XW0D3R Venetoclax Antineoplastic
-
XW0D3S COVID-19 Vaccine Dose 1
-
XW0D3S Iobenguane I-131 Antineoplastic
-
XW0D3T COVID-19 Vaccine Dose 2
-
XW0D3T Ruxolitinib
-
XW0D3U COVID-19 Vaccine
-
XW0D3U Imipenem-cilastatin-relebactam Anti-infective
-
XW0D3V COVID-19 Vaccine Dose 3
-
XW0D3V Gilteritinib Antineoplastic
-
XW0D3W Caplacizumab
-
XW0D3W COVID-19 Vaccine Booster
-
XW0D3X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW0D3X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW0D3Y Other New Technology Monoclonal Antibody
-
-
XW0D7 Via Natural or Artificial Opening
-
XW0D70 Brexanolone
-
XW0D70 Spesolimab Monoclonal Antibody
-
XW0D71 Daratumumab and Hyaluronidase-fihj
-
XW0D71 Eladocagene exuparvovec
-
XW0D72 Bromelain-enriched Proteolytic Enzyme
-
XW0D72 Nerinitide
-
XW0D73 Durvalumab Antineoplastic
-
XW0D73 Maribavir Anti-infective
-
XW0D74 Teclistamab Antineoplastic
-
XW0D75 Mosunetuzumab Antineoplastic
-
XW0D75 Narsoplimab Monoclonal Antibody
-
XW0D76 Afamitresgene Autoleucel Immunotherapy
-
XW0D76 Lefamulin Anti-infective
-
XW0D76 Terlipressin
-
XW0D77 Coagulation Factor Xa, Inactivated
-
XW0D77 Tabelecleucel Immunotherapy
-
XW0D77 Trilaciclib
-
XW0D78 Lurbinectedin
-
XW0D78 Mineral-based Topical Hemostatic Agent
-
XW0D78 Treosulfan
-
XW0D78 Uridine Triacetate
-
XW0D79 Ceftolozane/Tazobactam Anti-infective
-
XW0D79 Inebilizumab-cdon
-
XW0D79 Satralizumab-mwge
-
XW0D7A Cefiderocol Anti-infective
-
XW0D7A Ciltacabtagene Autoleucel
-
XW0D7B Amivantamab Monoclonal Antibody
-
XW0D7B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW0D7B Omadacycline Anti-infective
-
XW0D7C Eculizumab
-
XW0D7C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW0D7D Atezolizumab Antineoplastic
-
XW0D7D Engineered Allogeneic Thymus Tissue
-
XW0D7E Etesevimab Monoclonal Antibody
-
XW0D7E Remdesivir Anti-infective
-
XW0D7F Bamlanivimab Monoclonal Antibody
-
XW0D7F Other New Technology Therapeutic Substance
-
XW0D7G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW0D7G Plazomicin Anti-infective
-
XW0D7G REGN-COV2 Monoclonal Antibody
-
XW0D7G Sarilumab
-
XW0D7H Axicabtagene Ciloleucel Immunotherapy
-
XW0D7H Other New Technology Monoclonal Antibody
-
XW0D7H Synthetic Human Angiotensin II
-
XW0D7H Tocilizumab
-
XW0D7J Apalutamide Antineoplastic
-
XW0D7J Tisagenlecleucel Immunotherapy
-
XW0D7K Fosfomycin Anti-infective
-
XW0D7K Idecabtagene Vicleucel Immunotherapy
-
XW0D7K Leronlimab Monoclonal Antibody
-
XW0D7L CD24Fc Immunomodulator
-
XW0D7L Erdafitinib Antineoplastic
-
XW0D7L Lifileucel Immunotherapy
-
XW0D7M Baricitinib
-
XW0D7M Brexucabtagene Autoleucel Immunotherapy
-
XW0D7M Esketamine Hydrochloride
-
XW0D7N Lisocabtagene Maraleucel Immunotherapy
-
XW0D7N Meropenem-vaborbactam Anti-infective
-
XW0D7P Antibiotic-eluting Bone Void Filler
-
XW0D7Q Tagraxofusp-erzs Antineoplastic
-
XW0D7R Fostamatinib
-
XW0D7R Venetoclax Antineoplastic
-
XW0D7S COVID-19 Vaccine Dose 1
-
XW0D7S Iobenguane I-131 Antineoplastic
-
XW0D7T COVID-19 Vaccine Dose 2
-
XW0D7T Ruxolitinib
-
XW0D7U COVID-19 Vaccine
-
XW0D7U Imipenem-cilastatin-relebactam Anti-infective
-
XW0D7V COVID-19 Vaccine Dose 3
-
XW0D7V Gilteritinib Antineoplastic
-
XW0D7W Caplacizumab
-
XW0D7W COVID-19 Vaccine Booster
-
XW0D7X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW0D7X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW0D7Y Other New Technology Monoclonal Antibody
-
-
XW0D8 Via Natural or Artificial Opening Endoscopic
-
XW0D80 Brexanolone
-
XW0D80 Spesolimab Monoclonal Antibody
-
XW0D81 Daratumumab and Hyaluronidase-fihj
-
XW0D81 Eladocagene exuparvovec
-
XW0D82 Bromelain-enriched Proteolytic Enzyme
-
XW0D82 Nerinitide
-
XW0D83 Durvalumab Antineoplastic
-
XW0D83 Maribavir Anti-infective
-
XW0D84 Teclistamab Antineoplastic
-
XW0D85 Mosunetuzumab Antineoplastic
-
XW0D85 Narsoplimab Monoclonal Antibody
-
XW0D86 Afamitresgene Autoleucel Immunotherapy
-
XW0D86 Lefamulin Anti-infective
-
XW0D86 Terlipressin
-
XW0D87 Coagulation Factor Xa, Inactivated
-
XW0D87 Tabelecleucel Immunotherapy
-
XW0D87 Trilaciclib
-
XW0D88 Lurbinectedin
-
XW0D88 Mineral-based Topical Hemostatic Agent
-
XW0D88 Treosulfan
-
XW0D88 Uridine Triacetate
-
XW0D89 Ceftolozane/Tazobactam Anti-infective
-
XW0D89 Inebilizumab-cdon
-
XW0D89 Satralizumab-mwge
-
XW0D8A Cefiderocol Anti-infective
-
XW0D8A Ciltacabtagene Autoleucel
-
XW0D8B Amivantamab Monoclonal Antibody
-
XW0D8B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW0D8B Omadacycline Anti-infective
-
XW0D8C Eculizumab
-
XW0D8C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW0D8D Atezolizumab Antineoplastic
-
XW0D8D Engineered Allogeneic Thymus Tissue
-
XW0D8E Etesevimab Monoclonal Antibody
-
XW0D8E Remdesivir Anti-infective
-
XW0D8F Bamlanivimab Monoclonal Antibody
-
XW0D8F Other New Technology Therapeutic Substance
-
XW0D8G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW0D8G Plazomicin Anti-infective
-
XW0D8G REGN-COV2 Monoclonal Antibody
-
XW0D8G Sarilumab
-
XW0D8H Axicabtagene Ciloleucel Immunotherapy
-
XW0D8H Other New Technology Monoclonal Antibody
-
XW0D8H Synthetic Human Angiotensin II
-
XW0D8H Tocilizumab
-
XW0D8J Apalutamide Antineoplastic
-
XW0D8J Tisagenlecleucel Immunotherapy
-
XW0D8K Fosfomycin Anti-infective
-
XW0D8K Idecabtagene Vicleucel Immunotherapy
-
XW0D8K Leronlimab Monoclonal Antibody
-
XW0D8L CD24Fc Immunomodulator
-
XW0D8L Erdafitinib Antineoplastic
-
XW0D8L Lifileucel Immunotherapy
-
XW0D8M Baricitinib
-
XW0D8M Brexucabtagene Autoleucel Immunotherapy
-
XW0D8M Esketamine Hydrochloride
-
XW0D8N Lisocabtagene Maraleucel Immunotherapy
-
XW0D8N Meropenem-vaborbactam Anti-infective
-
XW0D8P Antibiotic-eluting Bone Void Filler
-
XW0D8Q Tagraxofusp-erzs Antineoplastic
-
XW0D8R Fostamatinib
-
XW0D8R Venetoclax Antineoplastic
-
XW0D8S COVID-19 Vaccine Dose 1
-
XW0D8S Iobenguane I-131 Antineoplastic
-
XW0D8T COVID-19 Vaccine Dose 2
-
XW0D8T Ruxolitinib
-
XW0D8U COVID-19 Vaccine
-
XW0D8U Imipenem-cilastatin-relebactam Anti-infective
-
XW0D8V COVID-19 Vaccine Dose 3
-
XW0D8V Gilteritinib Antineoplastic
-
XW0D8W Caplacizumab
-
XW0D8W COVID-19 Vaccine Booster
-
XW0D8X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW0D8X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW0D8Y Other New Technology Monoclonal Antibody
-
-
XW0DX External
-
XW0DX0 Brexanolone
-
XW0DX0 Spesolimab Monoclonal Antibody
-
XW0DX1 Daratumumab and Hyaluronidase-fihj
-
XW0DX1 Eladocagene exuparvovec
-
XW0DX2 Bromelain-enriched Proteolytic Enzyme
-
XW0DX2 Nerinitide
-
XW0DX3 Durvalumab Antineoplastic
-
XW0DX38Introduction of Maribavir Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 8
-
-
XW0DX3 Maribavir Anti-infective
-
XW0DX38Introduction of Maribavir Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 8
-
-
XW0DX4 Teclistamab Antineoplastic
-
XW0DX5 Mosunetuzumab Antineoplastic
-
XW0DX5 Narsoplimab Monoclonal Antibody
-
XW0DX6 Afamitresgene Autoleucel Immunotherapy
-
XW0DX66Introduction of Lefamulin Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 6
-
-
XW0DX6 Lefamulin Anti-infective
-
XW0DX66Introduction of Lefamulin Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 6
-
-
XW0DX6 Terlipressin
-
XW0DX66Introduction of Lefamulin Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 6
-
-
XW0DX7 Coagulation Factor Xa, Inactivated
-
XW0DX7 Tabelecleucel Immunotherapy
-
XW0DX7 Trilaciclib
-
XW0DX8 Lurbinectedin
-
XW0DX82Introduction of Uridine Triacetate into Mouth and Pharynx, External Approach, New Technology Group 2
-
-
XW0DX8 Mineral-based Topical Hemostatic Agent
-
XW0DX82Introduction of Uridine Triacetate into Mouth and Pharynx, External Approach, New Technology Group 2
-
-
XW0DX8 Treosulfan
-
XW0DX82Introduction of Uridine Triacetate into Mouth and Pharynx, External Approach, New Technology Group 2
-
-
XW0DX8 Uridine Triacetate
-
XW0DX82Introduction of Uridine Triacetate into Mouth and Pharynx, External Approach, New Technology Group 2
-
-
XW0DX9 Ceftolozane/Tazobactam Anti-infective
-
XW0DX9 Inebilizumab-cdon
-
XW0DX9 Satralizumab-mwge
-
XW0DXA Cefiderocol Anti-infective
-
XW0DXA Ciltacabtagene Autoleucel
-
XW0DXB Amivantamab Monoclonal Antibody
-
XW0DXB Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW0DXB Omadacycline Anti-infective
-
XW0DXC Eculizumab
-
XW0DXC Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW0DXD Atezolizumab Antineoplastic
-
XW0DXD Engineered Allogeneic Thymus Tissue
-
XW0DXE Etesevimab Monoclonal Antibody
-
XW0DXE Remdesivir Anti-infective
-
XW0DXF Bamlanivimab Monoclonal Antibody
-
XW0DXF5Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5
-
-
XW0DXF Other New Technology Therapeutic Substance
-
XW0DXF5Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5
-
-
XW0DXG Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW0DXG Plazomicin Anti-infective
-
XW0DXG REGN-COV2 Monoclonal Antibody
-
XW0DXG Sarilumab
-
XW0DXH Axicabtagene Ciloleucel Immunotherapy
-
XW0DXH Other New Technology Monoclonal Antibody
-
XW0DXH Synthetic Human Angiotensin II
-
XW0DXH Tocilizumab
-
XW0DXJ Apalutamide Antineoplastic
-
XW0DXJ5Introduction of Apalutamide Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5
-
-
XW0DXJ Tisagenlecleucel Immunotherapy
-
XW0DXJ5Introduction of Apalutamide Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5
-
-
XW0DXK Fosfomycin Anti-infective
-
XW0DXK Idecabtagene Vicleucel Immunotherapy
-
XW0DXK Leronlimab Monoclonal Antibody
-
XW0DXL CD24Fc Immunomodulator
-
XW0DXL5Introduction of Erdafitinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5
-
-
XW0DXL Erdafitinib Antineoplastic
-
XW0DXL5Introduction of Erdafitinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5
-
-
XW0DXL Lifileucel Immunotherapy
-
XW0DXL5Introduction of Erdafitinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5
-
-
XW0DXM Baricitinib
-
XW0DXM6Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6
-
-
XW0DXM Brexucabtagene Autoleucel Immunotherapy
-
XW0DXM6Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6
-
-
XW0DXM Esketamine Hydrochloride
-
XW0DXM6Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6
-
-
XW0DXN Lisocabtagene Maraleucel Immunotherapy
-
XW0DXN Meropenem-vaborbactam Anti-infective
-
XW0DXP Antibiotic-eluting Bone Void Filler
-
XW0DXQ Tagraxofusp-erzs Antineoplastic
-
XW0DXR Fostamatinib
-
XW0DXR Venetoclax Antineoplastic
-
XW0DXS COVID-19 Vaccine Dose 1
-
XW0DXS Iobenguane I-131 Antineoplastic
-
XW0DXT COVID-19 Vaccine Dose 2
-
XW0DXT5Introduction of Ruxolitinib into Mouth and Pharynx, External Approach, New Technology Group 5
-
-
XW0DXT Ruxolitinib
-
XW0DXT5Introduction of Ruxolitinib into Mouth and Pharynx, External Approach, New Technology Group 5
-
-
XW0DXU COVID-19 Vaccine
-
XW0DXU Imipenem-cilastatin-relebactam Anti-infective
-
XW0DXV COVID-19 Vaccine Dose 3
-
XW0DXV5Introduction of Gilteritinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5
-
-
XW0DXV Gilteritinib Antineoplastic
-
XW0DXV5Introduction of Gilteritinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5
-
-
XW0DXW Caplacizumab
-
XW0DXW COVID-19 Vaccine Booster
-
XW0DXX Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW0DXX Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW0DXY Other New Technology Monoclonal Antibody
-
-